Daletos Georgios, Ebrahim Weaam, Ancheeva Elena, El-Neketi Mona, Song Weiguo, Lin Wenhan, Proksch Peter
Institute of Pharmaceutical Biology and Biotechnology, Heinrich-Heine-University Dusseldorf, Universitatsstrasse 1, 40225 Dusseldorf, Germany.
Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
Curr Med Chem. 2018;25(2):186-207. doi: 10.2174/0929867324666170314150121.
Over the last two decades, deep-sea-derived fungi are considered to be a new source of pharmacologically active secondary metabolites for drug discovery mainly based on the underlying assumption that the uniqueness of the deep sea will give rise to equally unprecedented natural products. Indeed, up to now over 200 new metabolites have been identified from deep-sea fungi, which is in support of the statement made above.
This review summarizes the new and/or bioactive compounds reported from deepsea- derived fungi in the last six years (2010 - October 2016) and critically evaluates whether the data published so far really support the notion that these fungi are a promising source of new bioactive chemical entities.
在过去二十年中，深海来源的真菌被认为是药物发现中具有药理活性的次生代谢产物的新来源，这主要基于这样一个基本假设，即深海的独特性将产生同样前所未有的天然产物。事实上，到目前为止，已从深海真菌中鉴定出200多种新的代谢产物，这支持了上述说法。
本综述总结了过去六年（2010年至2016年10月）报道的来自深海真菌的新化合物和/或生物活性化合物，并批判性地评估了迄今为止发表的数据是否真的支持这些真菌是新的生物活性化学实体的有前景来源这一观点。
